Navigation Links
Kensey Nash Reports Second Quarter Fiscal Year 2011 Financial Results
Date:2/1/2011

U.S. and outside the U.S.  However, due to the significant cost and risk of obtaining U.S. regulatory approval with the uncertain U.S. regulatory climate, restrictive clinical requirements, protracted patient enrollment and extended follow up timeframe for the Company's cartilage technology in the U.S., the Company is shifting its clinical activities for the cartilage product outside the U.S.  The Company plans to reallocate its research and development funds towards products with more predictable near term regulatory approval criteria.

The Company currently expects that its operating margin will be approximately 33% in fiscal 2011 and its balance sheet will continue to be strengthened by adding cash from operations for the full fiscal year of approximately $20 million (excluding any in-process R&D charges and acquisition costs related to Nerites).

The Company is currently estimating that third quarter fiscal 2011 total revenues will be in the range of $18.5 to $19.0 million. Net sales are currently expected to be in the range of $11.7 to $12.1 million, and royalties are currently expected to be in the range of $6.8 to $6.9 million.  The Company currently expects third quarter fiscal 2011 diluted earnings per share of $0.42 to $0.44 (excluding any in-process R&D charges and acquisition costs related to Nerites).  

Stock Repurchase Update. During the six months ended December 31, 2010, the Company repurchased 1,175,738 shares of Common Stock, at a total cost of approximately $30.0 million, or an average market price of $25.52 per share, using available cash.  This completed the latest $30 million repurchase program.  The Company had 8,523,360 shares of Common Stock outstanding as of December 31, 2010.  

Income taxes.  The Company currently estimates that its fiscal 2011 effective tax rate will be between 32% and 33%.  In the course of estimating the Company's annual eff
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
3. Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
4. Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products
5. Kensey Nash to Present at the 2009 UBS Global Life Sciences Conference
6. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
7. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
10. Pharmos Corporation Reports 2008 Second Quarter Results
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... a biopharmaceutical company advancing patient care in critical areas, ... 3,500,000 shares of common stock, and warrants to purchase ... at an offering price of $4.00 per share and ... exercise price of $5.00, are exercisable immediately, and expire ...
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced ... treasurer for the American Society for Reproductive Medicine (ASRM), ... research in reproductive medicine. In his new role ... the executive board and will have a voice in ... has actively supported ASRM since 1984 when he joined ...
(Date:12/24/2014)... LONDON , December 23, 2014 ... Review Algeria , out today and available for free ... the actors driving change and growth in the sector today. ... has scored notable successes has been in developing a homegrown ... 70 percent local production still remains some way off. A ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:Stem Cell Innovations to Provide Research and Assay Services to Agennix. 2Stem Cell Innovations to Provide Research and Assay Services to Agennix. 3Stem Cell Innovations to Provide Research and Assay Services to Agennix. 4Stem Cell Innovations to Provide Research and Assay Services to Agennix. 5Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 2Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 3Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 4Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 5Cellular Dynamics and Roche Conduct 'Stem Cells in Drug Discovery and Development' Workshop at the Society of Toxicology Annual Meeting 6Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 2Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 3Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 4Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 5Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 6Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 7Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 8Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 9Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 10Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results 11
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Disease A group led by Dr. Gregory A. ... Bronx, NY has demonstrated that presenilin-1 plays a role in ... can be found in the January 2010 issue of the ... for half of all dementias diagnosed each year. Mutations ...
... the Arctic could face seasonally ice-free conditions and much warmer ... Arctic Ocean and Nordic Seas were too warm to support ... 3 million years ago). This period is characterized by warm ... century, and is used as an analog to understand future ...
... LEADS: (top news in natural science) ... Volcanoes can be catastrophic. Lava flows and debris avalanches ... areas. Scientists from the USGS work with partners around ... use seismometers to detect and monitor very small earthquakes ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Arctic could face warmer and ice-free conditions 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
... been developed specifically for the stabilization ... microwell plates/strips. Coating Stabilizer maintains ... antibody or protein antigen portion of ... is filtered at 0.2 microns., ,Contents: ...
... Block is an anodized aluminum, solvent-resistant block ... to provide efficient thermal transfer to samples ... of the HT96 Isothermal Block replaces Cat. ... design allowing for compatibility with robotic applications. ...
Biology Products: